Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).

12 novembre 2026 mis à jour par: Merck Sharp & Dohme LLC

Une étude multicentrique de phase 1b / 2 en ouverture pour évaluer l'innocuité et l'efficacité de Raludotatug derropxecan avec ou sans autres agents d'investigation anticancéreux chez les participants atteints de cancer de l'ovaire épithélial séreux de haut grade, de péritonéal primaire ou de cancer de la trompe de Fallope qui ont rechué après une chimiothérapie antérieure à base de platine à base de platine à base de platine à base de platine de platine de platine ou à la chimiothérapie par platine antérieure en platine de platine de platine de platine de platine de platine de platine de platine de platine de platine antérieure après une chimiothérapie de platine à platine antérieure après une chimiothérapie de platine antérieure à base de platine de platine de platine de platine de platine de platine CHIMORATYPE PLATINUM ARE PRÉNIM

Researchers are looking for other ways to treat high-grade serous and certain other ovarian cancer. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.

Standard treatment (usual treatment) for people with high-grade serous ovarian cancer may include:

  • Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing
  • Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread

Raludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.

Aperçu de l'étude

Description détaillée

This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.

Type d'étude

Interventionnel

Inscription (Estimé)

605

Phase

  • Phase 2
  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Victoria
      • St Albans, Victoria, Australie, 3021
        • Recrutement
        • Western Health-Sunshine & Footscray Hospitals ( Site 1002)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +61402775432
    • Ontario
      • Toronto, Ontario, Canada, M5G 2M9
        • Recrutement
        • Princess Margaret Cancer Centre ( Site 0101)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 416-946-2818
    • Quebec
      • Montreal, Quebec, Canada, H4A 3J1
        • Recrutement
        • McGill University Health Centre ( Site 0100)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 514-934-1934x31975
      • Montreal, Quebec, Canada, H2X 0A9
        • Recrutement
        • Centre Hospitalier de l'Université de Montréal ( Site 0102)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 514-890-8000
      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital ( Site 2000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82220723511
      • Seoul, Corée du Sud, 03722
        • Recrutement
        • Severance Hospital, Yonsei University Health System ( Site 2002)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82222282230
      • Seoul, Corée du Sud, 05505
        • Recrutement
        • Asan Medical Center ( Site 2003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82230103646
      • Seoul, Corée du Sud, 06351
        • Recrutement
        • Samsung Medical Center ( Site 2001)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 82234101382
    • Kyonggi-do
      • Goyang-si, Kyonggi-do, Corée du Sud, 10408
        • Recrutement
        • National Cancer Center ( Site 2004)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 82319201760
      • Barcelona, Espagne, 08035
        • Recrutement
        • Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +349325434528607
      • Madrid, Espagne, 28041
        • Recrutement
        • Hospital Universitario 12 de Octubre ( Site 0304)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34913908626
      • Madrid, Espagne, 28040
        • Recrutement
        • Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 34915504800 x2805
      • Málaga, Espagne, 29010
        • Recrutement
        • Hospital Universitario Virgen de la Victoria ( Site 0306)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34951032508
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, Espagne, 08908
        • Recrutement
        • Institut Català d'Oncologia - L'Hospitalet ( Site 0302)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34932607744
    • Madrid
      • Majadhonda, Madrid, Espagne, 28222
        • Recrutement
        • HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34 911917358
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espagne, 28027
        • Recrutement
        • Clinica Universidad de Navarra ( Site 0301)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +349135319207513
    • Valenciana, Comunitat
      • Valencia, Valenciana, Comunitat, Espagne, 46014
        • Recrutement
        • Hospital General Universitario de Valencia ( Site 0305)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34 963187527
      • Haifa, Israël, 3109601
        • Recrutement
        • Rambam Health Care Campus ( Site 0202)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 972-4-7776234
      • Jerusalem, Israël, 9103102
        • Recrutement
        • Shaare Zedek Medical Center ( Site 0201)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +972-(0)2-6555424
      • Petah Tikva, Israël, 4941492
        • Recrutement
        • Rabin Medical Center ( Site 0203)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +97239378076
      • Ramat Gan, Israël, 5265601
        • Recrutement
        • Sheba Medical Center ( Site 0200)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 972-3-5304498
      • Manchester, Royaume-Uni, M20 4BX
        • Recrutement
        • The Christie NHS Foundation Trust ( Site 0405)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +441619187689
    • East Sussex
      • Brighton, East Sussex, Royaume-Uni, BN2 1ES
        • Recrutement
        • University Hospitals Sussex NHS Foundation Trust ( Site 0404)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +44 01273 696 955
    • England
      • Fulham, England, Royaume-Uni, SW3 6JJ
        • Recrutement
        • Royal Marsden Hospital ( Site 0402)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +442078118084
      • Sutton, England, Royaume-Uni, SM2 5PT
        • Recrutement
        • The Royal Marsden NHS Foundation Trust. ( Site 0403)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +442078118084
    • London, City of
      • London, London, City of, Royaume-Uni, E1 1RD
        • Recrutement
        • Barts Health NHS Trust ( Site 0401)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 020 7377 7000
      • London, London, City of, Royaume-Uni, SE1 3SS
        • Recrutement
        • Guy s & St Thomas NHS Foundation Trust ( Site 0400)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +44 020 7188 7188
      • Sankt Gallen, Suisse, 9000
        • Recrutement
        • HOCH Health Ostschweiz ( Site 0801)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +41714941111
    • Canton of Basel-City
      • Basel, Canton of Basel-City, Suisse, 4031
        • Recrutement
        • University Hospital Basel-Gynecology & Gynecologic Oncology ( Site 0802)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +41613284214
    • Canton of Vaud
      • Lausanne, Canton of Vaud, Suisse, 1011
        • Recrutement
        • CHUV (centre hospitalier universitaire vaudois) ( Site 0800)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +41795567362
      • Taipei, Taïwan, 100225
        • Recrutement
        • National Taiwan University Hospital ( Site 3001)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +886223123456
      • Taoyuan, Taïwan, 33305
        • Recrutement
        • Chang Gung Medical Foundation-Linkou Branch ( Site 3002)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +88633281200
    • Connecticut
      • New Haven, Connecticut, États-Unis, 06510
        • Recrutement
        • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 203-785-2404
    • Kentucky
      • Louisville, Kentucky, États-Unis, 40202
        • Recrutement
        • The University of Louisville, James Graham Brown Cancer Center ( Site 0009)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 502-562-3429
    • Louisiana
      • Shreveport, Louisiana, États-Unis, 71103
        • Recrutement
        • TRIALS 365 ( Site 0020)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 318-408-1198
    • Massachusetts
      • Boston, Massachusetts, États-Unis, 02215
        • Recrutement
        • Dana-Farber Cancer Institute ( Site 0015)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 877-338-7425
    • New York
      • New York, New York, États-Unis, 10065
        • Recrutement
        • Memorial Sloan Kettering Cancer Center ( Site 0003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 212-639-2000
    • Oklahoma
      • Oklahoma City, Oklahoma, États-Unis, 73104
        • Recrutement
        • OU Health University of Oklahoma Medical Center ( Site 7000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 405-271-1112
    • Texas
      • Fort Worth, Texas, États-Unis, 76104
        • Recrutement
        • Texas Oncology - DFW ( Site 8000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 615-329-7430
      • Houston, Texas, États-Unis, 77030
        • Complété
        • Houston Methodist Hospital ( Site 0010)
    • Utah
      • West Valley City, Utah, États-Unis, 84119
        • Recrutement
        • START Mountain Region ( Site 0008)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 801-907-4750
    • Virginia
      • Charlottesville, Virginia, États-Unis, 22908
        • Recrutement
        • University of Virginia Health System ( Site 0011)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 434-924-9333

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Femelle

La description

Inclusion Criteria:

  • Has pathologically documented diagnosis of high-grade serous or high-grade endometrioid epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
  • Participants in Part 1 cohorts and Part 2 Cohort A-2 Arms 1, 2, and 3, Cohort B-2, and Cohort C-2 Arm 3: Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1
  • Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression <6 months (<180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen
  • Participants in Cohort B-1, Cohort B-2, Cohort C-2 Arm 3, Cohort E-1 and if administering bevacizumab is planned in Cohort D or Cohort A-2 Arms 1, 2, or 3: Is a candidate for bevacizumab treatment
  • Has provided tumor tissue for biomarker research (all cohorts)
  • Has an Eastern Cooperative Oncology Group performance status of 0 to 1
  • Participants in Cohort C-1, Cohort C-2 Arm 3, Cohort D, and Cohort E-1: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with poly-ADP ribose polymerase inhibitor (PARPi) in the first-line setting
  • Participants in Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)
  • Participants in Cohort C-2 Arms 1 and 2: Has a new, histologically confirmed diagnosis of International Federation of Gynecology and Obstetrics Stage III or Stage IV epithelial ovarian cancer (high-grade serous or high-grade endometrioid), fallopian tube cancer, or primary peritoneal cancer that is non-homologous recombination deficiency-positive
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, PARPi first-line maintenance treatment for non- homologous recombination deficiency (HRD)-positive disease is not the preferred option for the participant
  • Participants in Cohort C-2 Arms 1 and 2: According to the investigator's assessment, bevacizumab treatment for non-HRD-positive disease is not the preferred option for the participant

Exclusion Criteria:

  • Has any of the following within 6 months before allocation/randomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event
  • Has uncontrolled or significant cardiovascular disease
  • Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy
  • Has ≥Grade 2 peripheral neuropathy
  • Has received prior treatment with cadherin-6-targeted agents
  • Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation
  • Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids
  • Receives chronic steroid treatment
  • Has known additional malignancy that is progressing or has required active treatment within the past 3 years
  • Has known active CNS metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening
  • Has active infection requiring systemic therapy
  • HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)

Participants receive escalating doses of intravenous (IV) raludotatug deruxtecan (R-DXd) in combination with carboplatin at Dose 1. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive raludotatug deruxtecan until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Expérimental: Cohort A-1 Arm 2 (R-DXd + Paclitaxel)

Participants receive escalating doses of IV R-DXd in combination with paclitaxel. Participants can receive up to a maximum of six 3-week cycles of paclitaxel (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Expérimental: Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)

Participants receive escalating doses of intravenous (IV) R-DXd in combination with carboplatin at Dose 2. Participants can receive up to a maximum of six 3-week cycles of carboplatin (approximately 4 months) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

Expérimental: Cohort B-1 (R-DXd + Bevacizumab)

Participants receive escalating doses of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®
Expérimental: Cohort B-2 (R-DXd RP2D + Bevacizumab)

Participants with platinum-resistant recurrent ovarian cancer (PRROC) receive recommended Phase 2 dose (RP2D) of IV R-DXd in combination with bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®
Expérimental: Cohort C-1 (R-DXd + Pembrolizumab)

Participants receive escalating doses of IV R-DXd in combination with pembrolizumab. Participants can receive up to a maximum of thirty-five 3-week cycles of pembrolizumab (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Expérimental: Cohort D (R-DXd +/- Bevacizumab)

Participants with platinum-sensitive recurrent ovarian cancer (PSROC) receive IV R-DXd in combination with or without bevacizumab until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®
Expérimental: Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of carboplatin with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®
Expérimental: Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +/- Bevacizumab)

Participants with PSROC will receive the RP2D of R-DXd in combination with a maximum of 6 cycles of paclitaxel with or without bevacizumab, until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®
Comparateur actif: Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +/- Bevacizumab)

Participants with PSROC will receive one of 3 regimens of investigator's choice of platinum-based doublet chemotherapy with or without bevacizumab. Platinum-based doublet chemotherapy will be administered for maximum of 8 cycles. Bevacizumab can be administered until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®

IV injection on days 1 and 8 of each 3-week Cycle

IV injection administered on Day 1 of each 4-week cycle

Autres noms:
  • PLD
Expérimental: Cohort E-1 (R-DXd + MK-2010)

Participants receive escalating doses of IV R-DXd in combination with MK-2010. Participants can receive up to a maximum of thirty-five 3-week cycles of MK-2010 (approximately 2 years) and will receive R-DXd until disease progression or discontinuation.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.

IV infusion on Day 1 of every 3-week cycle

Expérimental: Cohort C-2 Arm 1 (Carboplatin + Paclitaxel + Pembrolizumab → R-DXd + Pembrolizumab)

Participants will receive carboplatin (Dose 1 or Dose 2), paclitaxel (five 3-week cycles), and pembrolizumab during the induction phase. During the maintenance phase, participants will receive RP2D of IV R-DXd (up to 2 years; participants with PR or SD at 2 years may continue until disease progression) in combination with pembrolizumab (up to thirty-five 3-week cycles).

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Expérimental: Cohort C-2 Arm 2 (Carboplatin + Paclitaxel)

Participants will receive carboplatin (Dose 1 or Dose 2) and paclitaxel (seven 3-week cycles), followed by standard of care observation.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.

Expérimental: Cohort C-2 Arm 3 (R-DXd + Pembrolizumab + Bevacizumab)

Participants with PSROC will receive RP2D of R-DXd in combination with pembrolizumab (up to thirty-five 3-week cycles) and bevacizumab until progressive disease.

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • MK-5909, R-DXD

IV infusion on Day 1 of every 3-week cycle.

Autres noms:
  • Comprend, en fonction de l'approvisionnement :
  • -Avastin®
  • -Alymsys®
  • -MVASI®
  • -Oyavas®
  • -Zirabev®
  • -Vegzelma®
  • - Aybintio®
  • - Breztri®

IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)
Délai: Up to 21 days

DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.

Up to 21 days
Part 1: Number of Participants with One or More Adverse Events (AEs)
Délai: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.

Up to approximately 3 years
Part 1: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Objective Response Rate (ORR)
Délai: Up to approximately 3 years

ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: Progression Free Survival (PFS) - Cohort C-2 Arm 1 and Arm 2
Délai: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Part 1: Objective Response Rate (ORR)
Délai: Up to approximately 3 years

ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).

Up to approximately 3 years
Part 2: Duration of Response (DOR)
Délai: Up to approximately 3 years

For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.

Up to approximately 3 years
Part 2: PFS - Cohort A-2 Arm 2 and Arm 3
Délai: Up to approximately 3 years

PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.

Up to approximately 3 years
Part 2: Overall Survival (OS)
Délai: Up to approximately 5 years

OS is defined as the time from the first dose of study treatment to death due to any cause.

Up to approximately 5 years
Part 2: Number of Participants with One or More AEs
Délai: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years
Part 2: Number of Participants who Discontinue Study Intervention Due to an AE
Délai: Up to approximately 3 years

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.

Up to approximately 3 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

15 avril 2025

Achèvement primaire (Estimé)

27 mars 2029

Achèvement de l'étude (Estimé)

7 février 2031

Dates d'inscription aux études

Première soumission

20 février 2025

Première soumission répondant aux critères de contrôle qualité

20 février 2025

Première publication (Réel)

25 février 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner